Mar 11, 2019 / 03:20PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD and Senior Research Analyst
Good morning, and welcome once again to Cowen & Company's 39th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to introduce one of our first companies, Biogen, one of the luminaries in the industry. Then we're going to do a fireside chat with CEO, Michel Vounatsos.
Michel, do you want to start with maybe some opening remarks?
Michel Vounatsos - Biogen Inc. - CEO & Director
Certainly. So good morning, everybody. And thank you for having Biogen and me.
We may make some forward-looking statements, so I refer you back to our SEC filing.
2018 was a very good year. Top line double digit. Bottom line, even stronger. And I would say more importantly, we have enriched and advanced our pipeline portfolio very well, beyond aducanumab. But for aducanumab also, we increased the POS based on the results of BAN2401. And we are very encouraged by the results of our ASO SOD1 program,
Biogen Inc at Cowen Health Care Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot